The Role of Ixekizumab in Non-radiographic Axial Spondyloarthritis

Overview

Journal Ther Adv Musculoskelet Dis

Date 2021 Jan 25

PMID 33488787

Citations 4

Authors

Bon San Koo

Tae-Hwan Kim

Affiliations

Soon will be listed here.

Abstract

Among patients with axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA) is distinguished from ankylosing spondylitis (AS) by a lack of obvious radiographic changes in the sacroiliac joint. Tumor necrosis factor inhibitor (TNFi) has been used as a highly effective treatment in patients with AS and has shown good efficacy and safety in clinical trials in patients with nr-axSpA. As the pathophysiological mechanism for axSpA has started to become better recognized, various drugs other than TNFi, all of which are related to the interleukin-17 (IL-17) axis, are being evaluated in patients with axSpA. IL-17 inhibitors, such as secukinumab and ixekizumab, are effective drugs for patients with AS. A recent clinical trial reported that ixekizumab, a monoclonal antibody against IL-17A, was also effective in patients with nr-axSpA. In a COAST-X study, ixekizumab was superior to a placebo for improving signs and symptoms in patients with nr-axSpA at weeks 16 and 52. The adverse events were no different from those found in previous ixekizumab studies, and no new safety signals were identified. However, when considering several IL-17 inhibitors, it is necessary to obtain sufficient data to identify the exacerbation of extra-articular manifestation. In terms of effectiveness and safety, ixekizumab may be an appropriate alternative to TNFi in nr-axSpA patients.

Citing Articles

The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.

Nam B, Kim T Immunotherapy. 2024; 16(9):569-580.

PMID: 38511247 PMC: 11290369. DOI: 10.2217/imt-2023-0015.

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center.

Chiu I, Tsai T Biomedicines. 2023; 11(6).

PMID: 37371813 PMC: 10296553. DOI: 10.3390/biomedicines11061718.

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence.

Braun J, Kiltz U, Buhring B, Baraliakos X Ther Adv Musculoskelet Dis. 2021; 13:1759720X211041854.

PMID: 34471428 PMC: 8404628. DOI: 10.1177/1759720X211041854.

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.

Atzeni F, Carriero A, Boccassini L, DAngelo S Immunotargets Ther. 2021; 10:141-153.

PMID: 33977094 PMC: 8104974. DOI: 10.2147/ITT.S259126.

References

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

Kim H, Kwon S, Jung K, Kim S, Baek H, Seo M . Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. PLoS One. 2016; 11(4):e0153816. PMC: 4839632. DOI: 10.1371/journal.pone.0153816. View

Dougados M, Cheng-Chung Wei J, Landewe R, Sieper J, Baraliakos X, Van den Bosch F . Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2019; 79(2):176-185. PMC: 7025731. DOI: 10.1136/annrheumdis-2019-216118. View

Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009; 68(6):770-6. DOI: 10.1136/ard.2009.108217. View

Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S . Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020; 6(1). PMC: 7046955. DOI: 10.1136/rmdopen-2019-001117. View

Jo S, Wang S, Lee Y, Kang S, Lee B, Han J . IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Res Ther. 2018; 20(1):115. PMC: 5992730. DOI: 10.1186/s13075-018-1582-3. View

Ward M, Deodhar A, Gensler L, Dubreuil M, Yu D, Khan M . 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019; 71(10):1599-1613. PMC: 6764882. DOI: 10.1002/art.41042. View

Flouri I, Markatseli T, Boki K, Papadopoulos I, Skopouli F, Voulgari P . Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol. 2018; 45(6):785-794. DOI: 10.3899/jrheum.170477. View

Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A . IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol. 1998; 161(11):6383-9. View

10.

Wright J, Bennett F, Li B, Brooks J, Luxenberg D, Whitters M . The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008; 181(4):2799-805. DOI: 10.4049/jimmunol.181.4.2799. View

11.

Koo B, Jo S, Kwon E, Shin J, Hur J, Kim T . Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis. Korean J Intern Med. 2019; 35(2):465-473. PMC: 7060997. DOI: 10.3904/kjim.2018.364. View

12.

Chang S, Dong C . A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007; 17(5):435-40. DOI: 10.1038/cr.2007.35. View

13.

Ghosh N, Ruderman E . Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis Res Ther. 2017; 19(1):286. PMC: 5741895. DOI: 10.1186/s13075-017-1493-8. View

14.

Allen R, OCallaghan C, McMichael A, Bowness P . Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol. 1999; 162(9):5045-8. View

15.

Shahrara S, Pickens S, Mandelin 2nd A, Karpus W, Huang Q, Kolls J . IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol. 2010; 184(8):4479-87. PMC: 2858914. DOI: 10.4049/jimmunol.0901942. View

16.

Schreiber S, Colombel J, Feagan B, Reich K, Deodhar A, McInnes I . Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019; 78(4):473-479. PMC: 6530077. DOI: 10.1136/annrheumdis-2018-214273. View

17.

Park E, Kim H, Jung S, Sung Y, Baek H, Lee J . The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med. 2020; 35(1):41-59. PMC: 6960050. DOI: 10.3904/kjim.2019.411. View

18.

Kim Y, Kim Y, Shim T, Koo B, Hong S, Lee C . Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014; 53(8):1477-81. DOI: 10.1093/rheumatology/keu041. View

19.

van der Heijde D, Gensler L, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A . Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020; 79(5):595-604. PMC: 7213320. DOI: 10.1136/annrheumdis-2020-216980. View

20.

Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych W, Citera G . Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014; 66(8):2091-102. DOI: 10.1002/art.38721. View